Peter Hillmen1. Show Affiliations » 1. Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds LS9 7TF, UK. peter.hillmen@nhs.net
Abstract
Entities: Disease
Mesh： See more » Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useChromosome DeletionChromosomes, Human, Pair 11Chromosomes, Human, Pair 13Chromosomes, Human, Pair 17Clinical Trials, Phase III as TopicCyclophosphamide/administration & dosageDisease ProgressionDisease-Free SurvivalDrug Administration ScheduleHumansImmunologic Factors/administration & dosageIn Situ Hybridization, FluorescenceLeukemia, Lymphocytic, Chronic, B-Cell/drug therapyLeukemia, Lymphocytic, Chronic, B-Cell/geneticsLeukemia, Lymphocytic, Chronic, B-Cell/mortalityLeukemia, Lymphocytic, Chronic, B-Cell/pathologyPrognosisRandomized Controlled Trials as TopicRemission InductionRituximabTime FactorsTreatment OutcomeVidarabine/administration & dosageVidarabine/analogs & derivatives
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedImmunologic FactorsRituximabCyclophosphamideVidarabinefludarabine
Year: 2010 PMID： 20888976 DOI： 10.1016/S0140-6736(10)61512-7
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321